A 58-year-old man with cirrhosis (Child-Pugh B) and a 3.5 cm solitary hepatocellular carcinoma in the right lobe, without vascular invasion or extrahepatic metastases, presents for treatment planning. Which is the drug of choice for systemic therapy if he is not a candidate for curative resection or transplantation?

Question

Accepted Answer

B. Atezolizumab + bevacizumab. ## First-Line Systemic Therapy for Advanced HCC

**Key Point:** Atezolizumab + bevacizumab is the preferred first-line systemic regimen for unresectable HCC based on the IMbrave150 trial, which demonstrated superior overall survival (OS) and time to progression (TTP) compared to sorafenib monotherapy.

### Evidence Base
The IMbrave150 trial (2020) established atezolizumab (anti-PD-L1 checkpoint inhibitor) + bevacizumab (anti-VEGF monoclonal antibody) as the new standard of care:
- **Median OS:** 19.2 months vs. 13.2 months (sorafenib)
- **Median TTP:** 6.8 months vs. 4.3 months (sorafenib)
- **Objective response rate:** 33.2% vs. 13.7% (sorafenib)

### Mechanism of Action
| Drug | Class | Target | Rationale |
|------|-------|--------|----------|
| Atezolizumab | Monoclonal antibody | PD-L1 checkpoint | Restores anti-tumor T-cell immunity |
| Bevacizumab | Monoclonal antibody | VEGF | Inhibits angiogenesis; synergizes with immunotherapy |

**Clinical Pearl:** The combination addresses two critical HCC pathways: immune evasion (via PD-L1) and neovascularization (via VEGF), resulting in durable responses and improved survival.

### Patient Eligibility
- **Unresectable HCC** (not a candidate for curative surgery/transplant)
- **ECOG performance status 0–1**
- **Child-Pugh A or B** (this patient is Child-Pugh B, eligible)
- **No prior systemic therapy** (first-line setting)

**High-Yield:** Atezolizumab + bevacizumab has replaced sorafenib as the preferred first-line regimen in major guidelines (ASCO, ESMO, AASLD) since 2020.

### Why Not Other Options?
- **Sorafenib:** Historical first-line (SHARP trial, 2008); now second-line after atezolizumab + bevacizumab failure
- **Lenvatinib:** Approved as first-line (REFLECT trial, 2018) with OS comparable to sorafenib; used if atezolizumab + bevacizumab contraindicated
- **Doxorubicin:** Systemic chemotherapy with poor efficacy in HCC; not standard of care

**Warning:** Do not confuse the older paradigm (sorafenib as first-line) with current practice; the 2020 IMbrave150 data shifted the standard.

Answer

A. Lenvatinib

Answer

C. Doxorubicin

Answer

D. Sorafenib

Explanation

First-Line Systemic Therapy for Advanced HCC

Evidence Base

Mechanism of Action

Patient Eligibility

Why Not Other Options?

Practice similar questions

Join our NEET PG community

Drug	Class	Target	Rationale
Atezolizumab	Monoclonal antibody	PD-L1 checkpoint	Restores anti-tumor T-cell immunity
Bevacizumab	Monoclonal antibody	VEGF	Inhibits angiogenesis; synergizes with immunotherapy